Aegerion Pharmaceuticals (AEGR) reported quarterly earnings results on Monday, May-16-2016. The company reported $-1.72 earnings per share for the quarter, missing the analyst consensus estimate by $-1.45. Analysts had a consensus of $-0.27. The company posted revenue of $35.70 million in the period, compared to analysts expectations of $43.00 million. The company’s revenue was down -39.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.55 EPS.
Aegerion Pharmaceuticals closed down -0.18 points or -9.42% at $1.73 with 8,97,668 shares getting traded on Friday. Post opening the session at $1.9, the shares hit an intraday low of $1.69 and an intraday high of $1.97 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
Aegerion Pharmaceuticals Inc. is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. The Company’s products include Juxtapid (lomitapide) and MYALEPT (metreleptin). Lomitapide is a small molecule microsomal triglyceride transfer protein which is marketed under the brand name Juxtapid (lomitapide) capsules (Juxtapid) in the United States as an adjunct to a low-fat diet and other lipid-lowering treatments. Lomitapide was also approved in the European Union under the brand name LOJUXTA (lomitapide) hard capsules (LOJUXTA) as a treatment for homozygous familial hypercholesterolemia (HoFH) in adults. Metreleptin is a recombinant human leptin analog that exerts its function by binding to and activating the human leptin receptor and is available as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.